Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177 dotatate + capecitabine
- Development stage
- Phase 2
- Lead developer
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
lutetium-177 dotatate + capecitabine is a combination therapy regimen being investigated for the treatment of aggressive, FDG-positive gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). The regimen consists of Peptide Receptor Radionuclide Therapy (PRRT) using lutetium-177 dotatate, which delivers targeted beta-radiation to cells expressing somatostatin receptor type 2 (SSTR2), combined with low-dose metronomic capecitabine. Capecitabine, an oral fluoropyrimidine carbamate, acts as a radiosensitizer and anti-angiogenic agent, potentially enhancing the efficacy of the radionuclide therapy. This specific combination is being evaluated in clinical trials led by the Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS.
- Other names
- Lu-PRRT + capecitabine177Lu-DOTATATE + capecitabineLu-PRRT Plus Capecitabine
02
Targets
SSTR2 (Somatostatin receptor type 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on lutetium-177 dotatate + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177 dotatate + capecitabine.